Skip Navigation

Annals of Oncology 2006 17(5):731-732; doi:10.1093/annonc/mdl095
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schouten, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schouten, H. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

editorial

Home treatment for intensive hematological therapies: who will benefit?

H. C. Schouten

University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, Netherlands

(E-mail: h.schouten@intmed.unimass.nl)

The first 10% of the full text of this article appears below.

The treatment of patients with acute leukemia underwent a significant change in the second half of the 20th century. It was increasingly recognized that standard dose chemotherapy only had a palliative effect and did not change the natural course of the disease. To achieve long-lasting survival it appeared to be necessary to obtain a complete remission [1Go]. Also, in elderly patients, it was recognized that only intensive treatment was . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?